

1 **Viral cultures, Polymerase Chain Reaction Cycle Threshold Values and**
2 **Viral Load Estimation for SARS-CoV-2 Infectious Potential Assessment**
3 **in Hematopoietic Stem Cell and Solid Organ Transplant Patients: A**
4 **Systematic Review.**

5 Tom Jefferson¹, Elizabeth A. Spencer², John M. Conly⁷, Elena C. Rosca³, Susanna Maltoni⁴, Jon
6 Brassey⁵, Igho J. Onakpoya¹, David H. Evans⁶, Carl J. Heneghan², Annette Plüddemann^{2*}.

7 ¹Department for Continuing Education, University of Oxford, UK

8 ²Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences,
9 University of Oxford, UK

10 ³Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

11 ⁴Division of Research and Innovation, IRCCS Azienda Ospedaliero-Universitaria di Bologna,
12 Bologna, Italy

13 ⁵Trip Database Ltd, Newport, UK

14 ⁶Li Ka Shing Institute of Virology and Dept. of Medical Microbiology & Immunology, University
15 of Alberta, Canada

16 ⁷Departments of Medicine, Microbiology, Immunology & Infectious Diseases, and Pathology &
17 Laboratory Medicine, Synder Institute for Chronic Diseases and O'Brien Institute for Public

18 Health, Cumming School of Medicine, University of Calgary and Alberta Health Services,

19 Calgary, Canada.

20 *Corresponding author

21

22

23 **Abstract**

24 Background: Organ transplant recipients are at increased vulnerability to SARS-CoV-2 due to
25 immunosuppression and may pose a continued transmission risk especially within hospital
26 settings. Detailed case reports including symptoms, viral load and infectiousness, defined by the
27 presence of replication-competent viruses in culture, provide an opportunity to examine the
28 relationship between clinical course, burden and contagiousness, and provide guidance on
29 release from isolation.

30 Objectives: We performed a systematic review to investigate the relationship in transplant
31 recipients between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or cycle of
32 quantification value (Cq), or other measures of viral burden and the likelihood and duration of
33 the presence of infectious virus based on viral culture including the influence of age, sex,
34 underlying pathologies, degree of immunosuppression, and/or vaccination on this relationship.

35 Methods: We searched LitCovid, medRxiv, Google Scholar and WHO Covid-19 databases, from 1
36 November 2019 until 31 December 2021. We included studies reporting relevant data for
37 transplantees with SARS-CoV-2 infection: results from serial RT-PCR testing and viral culture
38 data from the same respiratory samples. We assessed methodological quality using five criteria,
39 and synthesised the data narratively and graphically.

40 Results: We included 10 case reports and case series reporting on 38 transplantees. We
41 observed a relationship between proxies of viral burden and likelihood of shedding replication-
42 competent SARS-CoV-2. Two individuals shed replication-competent viruses over 100 days after
43 infection onset. Lack of standardisation of testing and reporting platforms precludes

44 establishing a definitive viral burden cut-off. However, most transplantees stopped shedding
45 competent viruses when the RT-PCR cycle threshold was above 30 despite differences across
46 platforms.

47 Conclusions

48 Viral burden is a reasonable proxy for infectivity when considered within the context of the
49 clinical status of each patient. Standardised study design and reporting are essential to
50 standardise guidance based on an increasing evidence base.

51

52

53

54

55

56 **Keywords**

57 COVID-19; SARS-CoV-2; transmission; organ transplants; viral culture; polymerase chain
58 reaction; viral load; cycle threshold calibration; infectivity

59

60 Introduction

61 Hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients have
62 significant immunosuppression, affecting both cellular and humoral immunity, and less
63 favourable outcomes with Severe Acute Respiratory Virus Syndrome 2 (SARS-CoV-2) infection,
64 due to the immunosuppression and/or to pre-existing comorbidities¹. Immunosuppression
65 associated with transplantation places patients at risk for prolonged carriage and shedding of
66 several respiratory viruses². However, identification of respiratory viral shedding, recently by
67 reverse transcriptase polymerase chain reaction (RT-PCR), depending on the testing platform
68 does not correlate with the presence of replication-competent virus³. Accordingly, we sought to
69 perform a systematic review of RT-PCR testing and viral culture of SARS-CoV-2, focussing on
70 people receiving solid organ or hematopoietic stem cell transplants, following our published
71 protocol⁴.

72 Our research questions were:

- 73 1. What is the correlation between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or
74 cycle of quantification value (Cq), or other measures of viral burden and the likelihood
75 of producing replication-competent virus?
- 76 2. What is the likelihood and duration of the presence of infectious virus based on viral
77 culture, among transplant recipients with SARS-CoV-2 infection?
- 78 3. What is the influence of age, sex, underlying pathologies and degree of
79 immunosuppression on infectiousness of SARS-CoV-2?

80 4. What is the relationship of vaccination status on infectiousness with SARS-CoV-2?

81 We included studies reporting serial Cts from sequential RT-PCR testing or other measures of
82 viral burden such as RNA gene copies of respiratory samples (from nasopharyngeal or throat
83 specimens) along with viral culture data on the same samples, from patients about to receive a
84 transplant or who were post-transplant, with SARS-CoV-2 infection.

85 **Methods**

86 **Search Strategy**

87 We searched the following electronic databases: LitCovid, medRxiv, Google Scholar and the
88 WHO Covid-19 database from November 2019 until December 31, 2021. No language
89 restrictions were applied.

90 The literature search terms were: (coronavirus OR covid-19 OR SARS-CoV-2) AND
91 (immunosuppressed OR immunocompromised OR transplant OR immunosuppression OR
92 "immune deficient" OR HIV) AND (CPE OR "cytopathic effect" OR "Viral culture" OR "virus
93 culture" OR vero OR "virus replication" OR "viral replication" OR "cell culture" or "viral load" OR
94 "viral threshold" OR "log copies" OR "cycle threshold").

95 **Screening**

96 Four reviewers independently screened titles and abstracts to identify studies for consideration
97 of full text. Full text screening was performed in duplicate and disagreements arbitrated by a
98 fifth reviewer.

99 **Inclusion criteria**

100 We included studies reporting serial Cts from sequential RT-PCR testing, or RNA gene copies of
101 respiratory samples (nasopharyngeal, throat, sputum, bronchoalveolar lavage, endotracheal
102 tube secretions) AND viral culture data from the same samples from patients about to receive a
103 transplant or post-transplant with SARS-CoV-2 infection. We included primary studies provided
104 they reported sufficient information to extract quantitative data on the PCR testing and the
105 viral culture for each included individual. Studies that included transplant and non-transplant
106 patients were included if we could ascertain the results separately. Studies reported only in
107 poster or abstract form were excluded. Reviews were excluded but the reference lists screened
108 for potential relevant primary studies.

109 **Exclusion criteria**

110 We excluded studies using post-mortem samples only and non-respiratory samples only. We
111 did not include studies of non-transplant patients or those not attempting viral cultures.

112 **Data extraction**

113 One reviewer extracted data, which was independently checked by a second reviewer.
114 Disagreements were arbitrated by a third reviewer. Data were extracted on study type and
115 study characteristics, including population, setting, sampling and laboratory methods, clinical
116 information, prescribed treatments, vaccination status, laboratory findings, and clinical
117 outcomes. For three studies we sought clarification from the corresponding authors.

118 **Quality assessment**

119 We assessed the quality of included studies according to five criteria:

- 120 1. Were the criteria for diagnosing a case clearly reported and appropriate?
- 121 2. Was the reporting of patient/population characteristics including clinical symptoms,
122 treatments with degree of immunosuppression and outcomes adequate?
- 123 3. Was the study period, including follow-up, sufficient to adequately assess any potential
124 relationship between viral burden measures and likelihood of producing replication-
125 competent virus and the rise in neutralising antibodies? We defined sufficient as more
126 than one observation.
- 127 4. Were the methods used to obtain RT-PCR results replicable, generalisable and
128 appropriate? We considered that each study should establish the relationship between
129 their Ct values and the target gene copy number, using internal standards.
- 130 5. Were the methods used to obtain viral culture results replicable and appropriate? We
131 considered the methods used should, at a minimum, include a description of specimen
132 sampling and management, preparation, media and cell line used, exclusion of
133 contamination or co-infection (use of good controls and appropriate antibacterials and
134 antimycotics and possible use of gene sequencing if available), and results of inspection
135 of culture.

136 **Data reporting and pooling**

137 We reported study flow according to PRISMA reporting standards⁵. We reported study
138 characteristics including age, sex, clinical symptoms, treatments and events in the participants

139 in tabular form. We presented data on disease burden measures and on viral culture in tabular
140 form. For studies reporting more than one patient participant, data were extracted related to
141 each participant if available. We plotted median, interquartile ranges (IQRs) and outliers for
142 viral culture results in relation to the duration of symptoms, and individual study plots to day
143 120 of viral culture results and cycle thresholds.

144 We were unable to meta-analyse the data on PCR cycle counts/RNA log copies and viral culture,
145 due to a lack of detailed information on laboratory practices, assays and because of the
146 absence of internal controls in some studies, and heterogeneous sampling. We therefore
147 reviewed the studies narratively, and where possible presented the results graphically within
148 the limitations noted.

149 We analysed the relationship between cycle threshold, days of onset of symptoms and
150 likelihood of shedding replication-competent virus by presenting the data on a scatter plot

151 **Results**

152 The literature search identified 12,988 titles for screening. Of these 63 underwent full-text
153 review. A total of 53 studies were excluded after full-text analysis: reasons are reported in the
154 list of excluded studies (see Supplementary File: List of excluded studies)

155 The 10 included studies (Figure 1 reported data for 30 transplant patients (7 females and 23
156 males): renal (21), cardiac (5), bone marrow transplant (9), liver (2), bilateral lung (1). For one
157 study the number of males and females was not available for the relevant patient group .⁶ The
158 38 patients were in seven countries: Saudi Arabia⁷, France^{8 9}, Germany^{10 11 12}, Austria¹³,

159 Denmark¹⁴, Canada¹⁵ and the USA⁶, and were aged between 26 and 77 years old.

160 A total of 36 were infected with SARS-CoV-2 post-transplant: 21 patients in 3 studies had had
161 kidney transplant^{7 8 12}, 5 patients in 4 studies had had a cardiac transplant^{7 10 15 9}, 1 previous
162 bone marrow transplant for multiple myeloma¹⁴, 1 liver transplant¹⁴ and eight hematopoietic
163 cell transplants⁶. Two patients were infected with SARS-CoV-2 and subsequently underwent
164 transplant: 1 liver transplant¹¹, 1 patient had bilateral lung transplantation after a SARS-CoV-2
165 infection that severely affected the lungs¹³.

166 Typically, patients received⁶ a mixture of antivirals, antibiotics, convalescent plasma and
167 immune suppressants, as reported in Table 1. The clinical course of COVID-19 varied widely
168 amongst the included patients, from mild COVID-19 related symptoms to severe pneumonia
169 and lung failure; no deaths were specifically reported for this group, although deaths were
170 reported for 4 aggregate patients in one study within 30 days of diagnosis⁶. Prescribed
171 treatments reflected the variation in severity.

172 ***Quality Assessment***

173 Table 2 reports study quality based on five criteria. Three studies^{15 9 12} met all five criteria.
174 Follow-up was judged adequate in all studies; in nine studies the reporting of patient
175 characteristics was sufficiently comprehensive^{6 8 10 13 11 14 15 9 12} and clinical information was
176 missing for one study⁷. Case definition was missing or unclear in four studies^{6, 7 10 14}, and
177 methods for RT-PCR testing were unclear for three studies^{6 10 13}. The methods used for viral
178 culture were unclear in four studies^{7 10 13 11} and one study reported using a cell line that has
179 not typically been used to demonstrate SARS-CoV-2 growth - Buffalo green monkey kidney

180 (BGMK) cell line⁸.

181 ***Results of the studies***

182 The results are reported in Table 1 and Table 3. The clinical course of infection was highly
183 variable (Tables and 1 and 3, and Figures 2 and 3). The time from transplant to infection varied
184 from days to years (see for example Aydillo et al⁶ and Rajakumar et al¹⁵). Sampling schedules
185 varied between studies, with no regular timetable of testing taking place, so results for PCR and
186 viral culture are available for different time points in a patient's clinical course and with
187 different gaps in time between samples being taken.

188 In response to our first study question on the correlation between proxy indicators of viral
189 burden and infectiousness, the data from Figures 2 and 3 and Table 3 indicate a correlation
190 between viral burden (measured as log copies or Cq/Ct) and probable infectiousness. The data
191 suggests that earlier symptom onset is related to the likelihood of shedding replication-
192 competent virus (Figure 2). The median time for a positive culture from onset of symptoms was
193 16 days (IQR 8 to 27; range 1-105, mean 19.7 days n = 59 cultures performed). The median for a
194 negative culture was 40 days, mean 40.2 days (IQR 22 to 60; range 1-119, n = 107 cultures
195 performed).

196 Five patients reported by Alshukairi et al were all culture-negative; this was in samples taken on
197 days 9,12, 17,18 and day 26 since symptom onset, respectively ⁷.

198 Seven stem cell transplant recipients from the Aydillo et al letter who had repeated culture
199 assessments fluctuated in and out of shedding replication-competent virus. One who had a

200 single culture attempt was positive with an estimated Ct of 17.5⁶. Patient MSK-6 shed
201 replication competent virus until day 62 from symptom onset with an estimated Ct of 19. MSK-
202 6 showed the longest duration infectious transplant recipient from the Aydillo et al letter⁶.
203 Eight kidney transplant patients described by Benotmane and colleagues had positive viral
204 cultures⁸.

205 For six patients we could identify the duration of probable infectiousness, which ranged from 8
206 days (patient 5: day 1 to 8) to 32 days (patient 7: day 7 to 38). Four patients were infectious
207 with reported Cts > 30 based on the individual platforms that were used to perform the Cts.

208 Rajakumar et al¹⁵ described two cardiac transplant patients: viral culture found replication-
209 competent virus in samples from one patient on day 16 and in samples from the other patient
210 on day 4 and repeatedly up to day 27, after which all viral cultures were negative¹⁵. For each
211 patient, viral culture was negative (i.e. no replication-competent virus observed) in samples
212 with PCR cycle counts of over 25. Within the samples giving positive viral cultures, the PCR
213 results showed that the cycle threshold for the N gene was lower than for the E gene by an
214 average of 5.4 Ct values.

215 In the study by Niyonkuru et al, the duration of infectiousness in the two patients, as indicated
216 by replication-competent virus, was 8 and 9 days (Figure 3)¹⁴. A cardiac transplant patient
217 described by Tarhini⁹ and colleagues tested culture-positive with a Ct of 23 on day 103; all other
218 viral cultures were negative from samples with PCR Cts of 18 to over 40⁹.

219 Weigang et al¹² described a kidney transplant patient who experienced three hospital

220 admissions. During the first one (day zero to day 72), 19 RT-qPCR tests were performed, and
221 alongside that viral culture was performed, showing 8/19 positive cultures (Ct values ranging
222 from 15 to 25) and 11/19 negative (Ct values from 25 to 30). The patient was culture positive
223 again on day 105 (Ct of 23). After re-admission at day 140 the patient was still RT-qPCR positive,
224 but with viral culture negative; he was treated for 10 days (days 141-149) with remdesivir.
225 Subsequently, negative RT-qPCR tests until day 189 and negative cultures suggested that the
226 infection had resolved¹².

227 A heart transplant patient described by Decker¹⁰ and co-workers had a positive viral culture on
228 day 18 and day 21 with 6.2 and 6.5 log₁₀ copies/ml.¹⁰

229 Although the dataset was limited, we observed an inverse relationship (Ct/Cq) or direct
230 relationship (log copies): the viral burden indicated by these methods correlated with
231 infectiousness, as shown by the ability to produce replication-competent virus in culture. The
232 presence of replication-competent virus reflects one of the highest grades of evidence
233 supporting the capability for forward transmission of SARS-CoV-2^{16, 17}.

234 The robustness of the correlation is difficult to assess because laboratory methods differ; it was
235 not possible to pool the data to produce a summary cut-off value for infectiousness, due to
236 these variations and due to varying time windows for sampling from patients (see Figure 2 and
237 Table 3).

238 In response to our second research question (on the likelihood and duration of infectiousness
239 among transplant recipients with SARS-CoV-2 infection) the data indicate that regardless of
240 differences in laboratory practices, observed prolonged shedding of replication-competent

241 virus is associated with alternating increases and decreases of viral burden over time, which in
242 some cases may be up to around 100 days^{9 12}.

243 Figure 4 shows the relationship between cycle threshold, symptom onset (in days) and
244 likelihood of shedding replication competent virus. In Benotmane, five results were reported
245 with a CT of 30 or above for a positive culture. [8] However, the cell line used in this study is not
246 demonstrated to support SARS-CoV-2 growth. In the other studies, despite a minimum of 10 different
247 PCR platforms being used and different culture techniques, the culture results are insensitive to
248 cycle thresholds above 30. The viral load estimates are affected by administration of courses of
249 anti-viral treatment including remdesivir. See Figures 3a (Cts/Cqs) and 3b (log copies).

250 Responding to our third research question (the influence of age, sex, underlying pathologies
251 and degree of immunosuppression on infectiousness): at present the heterogeneity and limited
252 amount of the available data preclude answering this question.

253 We are unable to answer our fourth and final research question on the relationship of
254 vaccination status on infectiousness because no study reported on vaccination status for these
255 transplant patients.

256

257 **Discussion**

258 This review included 10 reports of studies using viral culture and RT-qPCR testing among 38
259 transplant patients with immunosuppressive treatment who experienced COVID-19 infection.
260 The evidence indicates a relationship between indicators of viral burden (Ct, Cq or RNA log
261 copies) and probable infectiousness as indicated by the presence of replication-competent
262 virus. Gaps in the data remain due to variable methods and reporting and establishing summary
263 estimates of the relationship has not been possible. The data show a long-term rise and fall of
264 viral burden associated with the likelihood of infectiousness that in some transplant patients
265 appears to be a sequential pattern of going in and out of infectiousness. Replication-competent
266 virus was most commonly observed in samples with PCR Ct values under 25; one study was an
267 exception to this by reporting viable virus at Ct>30, but the use of a cell line not typically used
268 for SARS-CoV-2 isolation makes interpretation unclear⁸. The duration of viral RNA shedding was
269 variable, with the longest duration reported at 105 days¹². Our findings suggest a Ct of 30 or
270 greater, regardless of the platform, may be used as a reasonable proxy to rule out infectious
271 SARS-CoV-2 as there is a consistent correlation between a rising Ct value and likelihood of
272 isolating replication-competent virus. Such a value would be useful to guide clinicians managing
273 these difficult patients, particularly if there were repeated values in this range. Below a Ct of 30,
274 clinicians may choose to repeat NP or throat swabs to assess the direction of the Ct values to
275 allow a more dynamic assessment which taken in conjunction with the clinical status may
276 facilitate decision making for isolation or antiviral treatment considerations.

277

278 Regarding our third review question on the influence of patient variables on the likelihood of
279 the presence of infectious SARS-CoV-2, the included studies showed substantial heterogeneity;
280 some had missing data or few cultures available, and meta-analysis or pooling was not possible.

281 Variability in the clinical course of SARS-CoV-2 infection among transplant recipients has been
282 reported, including observed prolonged viral shedding¹⁸. Antiviral drugs may impact on these
283 observations, especially symptoms and viral burden.¹⁹

284 Two well-designed studies on immunosuppressed patients, which we were unable to include
285 because disaggregated data solely for transplant patients were not fully available, support our
286 conclusions^{6,20}. While this review is limited to transplant patients, evidence suggests similar
287 prolonged viral cultures are found in immunosuppressed cancer patients. We plan to perform a
288 further review in this group analysing the type of cancer and the impact of immunotherapies on
289 viral culture findings.

290 The transplant patient population is of particular importance: clinicians need guidance as to
291 when to release the patient from quarantine or isolation, given the heavy burden of
292 immunosuppression. We have tried to narrow the uncertainty and offer some general guidance
293 as to when patients are unlikely to be shedding replication-competent virus, but clinical
294 assessment of each patient must inform that decision because each patient and setting is
295 different.

296 The strengths of this review are that we followed our published protocol, entailing rigorous
297 literature searches, double checked data extraction and quality assessment, and a high level of
298 clinical and epidemiological expertise input to deliberate the findings. We were also able to

299 include data from an additional 8 transplant recipients after extensive correspondence with the
300 study authors⁶. Limitations include the small number of studies with viral culture and serial viral
301 load estimates among transplant patients, high variability in study design and reporting and
302 impossibility to pool results due to the well-known variability in sensitivity across assays²¹.

303 Case series are conventionally considered low in the evidence hierarchy, as they may entail
304 inherent bias in the selection of study participants and therefore have limited generalisability;
305 however, here they are essential in providing the detailed reports needed for this unusual
306 patient group. The case reports included here comprise some of the most detailed longitudinal
307 reports of this patient group for whom data are needed. The evidence base is limited, however,
308 by heterogeneous design and reporting within the studies with, for example, different
309 observation windows for reporting of viral burden and culturability or clinical characteristics of
310 patients.

311 In addition to providing appropriate care for the individual patient, ongoing transmission of
312 SARS-CoV-2 is a concern, and immunosuppressed individuals may pose a challenge by
313 experiencing prolonged carriage of the virus that could lead to forward transmission. Based on
314 our findings we would offer the following general guidance to clinicians:

315 Physicians who are experienced with these immunosuppressed patient populations should
316 work with public health to direct their isolation and quarantine requirements. Infectious
317 patients with immunosuppressive treatment following solid organ or stem cell transplantation
318 should be isolated until at least two consecutive respiratory specimens collected ≥ 24 hours
319 apart demonstrate a rising RT-PCR Ct (i.e. indicating diminishing viral burden). After discharge,

320 they should be closely followed up for SARS-CoV-2 infection for several weeks to months,
321 depending on the individual clinical scenario.

322 For obtaining data, standardisation of methods is needed: each laboratory should use
323 consistently applied platforms with suitable internal standards to calibrate the relationship
324 between Ct and genome copy in these patient populations.

325 Publication of results of case series or other longitudinal study should be reported in a
326 standardised format to avoid loss of data. We suggest observation windows should be within a
327 short range of 3 to 7 days during the acute periods post-transplantation and during periods of
328 rejection when higher doses of immunosuppressants are employed, depending on clinical
329 circumstances. Each observation window should include a summary of symptoms and
330 interventions, the reporting of PCR cycle threshold and, for samples with Ct below 30, attempts
331 at viral culture if available. Description of patients should include past medical histories and
332 details of treatments received. Observed drug interactions should be highlighted. Reasons for
333 admission, discharge and changes in isolation should be clearly reported. To investigate the
334 duration of viral shedding, studies should report the time between the first positive and the
335 first negative viral cultures.

336 With additional data gathering and standardisation of methods, it will be possible for transplant
337 physicians to develop evidence-based approaches to dealing with these patients for the benefit
338 of the patients and their families and the community at large.

339

340 **Acknowledgements**

341 We gratefully acknowledge the contributions of Drs Mini Kamboj and Jeroen van Kampen
342 who provided additional data from their studies and helped us to progress this work.

343

344 **Funding**

345 This work is supported by the National Institute for Health Research School for Primary
346 Care Research [Project 569] and by the University of Calgary.

347

348 **Author contributions**

349 TJ, CH and JC designed the study. JB performed the literature searches. JB, TJ, SM, ER and
350 ES, screened the studies for eligibility and performed data extraction. Additional expertise
351 on clinical and laboratory issues was given by DE, JC, SM and ER. CH generated the data
352 figures. All authors contributed to interpreting and writing up the results and conclusions.

353

354 **Ethics declarations**

355 Ethics approval and consent to participate:

356 This is a systematic review and meta-analysis. Therefore, ethical approval is not applicable.

357 Consent for publication:

358 Not applicable.

359

360 **Availability of data and materials**

361 All data generated or analysed during this study are included in this published article [and its
362 supplementary information files].

363

364 **Competing Interests**

365 TJ's competing interests are accessible at: [https://restoringtrials.org/competing-interests-tom-
366 jefferson](https://restoringtrials.org/competing-interests-tom-jefferson)

367 CJH holds grant funding from the NIHR, the NIHR School of Primary Care Research, the NIHR
368 BRC Oxford and the World Health Organization for a series of Living rapid review on the modes
369 of transmission of SARs-CoV-2 reference WHO registration No2020/1077093. He has received
370 financial remuneration from an asbestos case and given legal advice on mesh and hormone
371 pregnancy tests cases. He has received expenses and fees for his media work including
372 occasional payments from BBC Radio 4 Inside Health and The Spectator. He receives expenses
373 for teaching EBM and is also paid for his GP work in NHS out of hours (contract Oxford Health
374 NHS Foundation Trust). He has also received income from the publication of a series of toolkit
375 books and for appraising treatment recommendations in non-NHS settings. He is Director of
376 CEBM and is an NIHR Senior Investigator.

377 DE holds grant funding from the Canadian Institutes for Health Research and Li Ka Shing
378 Institute of Virology relating to the development of Covid-19 vaccines as well as the Canadian
379 Natural Science and Engineering Research Council concerning Covid-19 aerosol transmission.
380 He is a recipient of World Health Organization and Province of Alberta funding which supports
381 the provision of BSL3-based SARS-CoV-2 culture services to regional investigators. He also holds
382 public and private sector contract funding relating to the development of poxvirus-based Covid-
383 19 vaccines, SARS-CoV-2-inactivation technologies, and serum neutralization testing.

384 JMC holds grants from the Canadian Institutes for Health Research on acute and primary care
385 preparedness for COVID-19 in Alberta, Canada and was the primary local Investigator for a
386 *Staphylococcus aureus* vaccine study funded by Pfizer for which all funding was provided only to
387 the University of Calgary. He is co-investigator on a WHO funded study using integrated human
388 factors and ethnography approaches to identify and scale innovative IPC guidance
389 implementation supports in primary care with a focus on low-resource settings and using drone
390 aerial systems to deliver medical supplies and PPE to remote First Nations communities during
391 the COVID-19 pandemic. He also received support from the Centers for Disease Control and
392 Prevention (CDC) to attend an Infection Control Think Tank Meeting. He is a member and Chair
393 of the WHO Infection Prevention and Control Research and Development Expert Group for
394 COVID-19 and a member of the WHO Health Emergencies Programme (WHE) Ad-hoc COVID-19
395 IPC Guidance Development Group, both of which provide multidisciplinary advice to the WHO
396 and for which no funding is received and from which no funding recommendations are made
397 for any WHO contracts or grants. He is also a member of the Cochrane Acute Respiratory
398 Infections Working Group.

399 JB is a major shareholder in the Trip Database search engine (www.tripdatabase.com) as well as
400 being an employee. In relation to this work Trip has worked with a large number of
401 organisations over the years, none have any links with this work. The main current projects are
402 with AXA and SARS-CoV-2 (WHO Registration 2020/1077093-0) and is part of the review group
403 carrying out rapid reviews for Collateral Global. He worked on Living rapid literature review on
404 the modes of transmission of SARS-CoV-2 and a scoping review of systematic reviews and meta-
405 analyses of interventions designed to improve vaccination uptake (WHO Registration
406 2021/1138353-0).

407 ECR was a member of the European Federation of Neurological Societies (EFNS) / European
408 Academy of Neurology (EAN) Scientist Panel, Subcommittee of Infectious Diseases (2013 to
409 2017). Since 2021, she is a member of the International Parkinson and Movement Disorder
410 Society (MDS) Multiple System Atrophy Study Group, the Mild Cognitive Impairment in
411 Parkinson Disease Study Group, and the Infection Related Movement Disorders Study Group.
412 She was an External Expert and sometimes Rapporteur for COST proposals (2013, 2016, 2017,
413 2018, 2019) for Neurology projects. She is a Scientific Officer for the Romanian National Council
414 for Scientific Research.

415 AP holds grants from the NIHR School for Primary Care Research.

416 IJO and EAS have no interests to disclose.

417 SM is a pharmacist working for the Italian National Health System since 2002 and a member of
418 one of the three Institutional Review Boards of Emilia-Romagna Region (Comitato Etico Area
419 Vasta Emilia Centro) since 2018.

420

421

422 References

423

- 424 1. Jering, K.S., et al., *Excess mortality in solid organ transplant recipients hospitalized with COVID-*
425 *19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19.* Clin
426 Transplant, 2022. **36**(1): p. e14492. 10.1111/ctr.14492.
- 427 2. Andersen, K.M., et al., *Long-term use of immunosuppressive medicines and in-hospital COVID-19*
428 *outcomes: a retrospective cohort study using data from the National COVID Cohort*
429 *Collaborative.* (2665-9913 (Electronic)).
- 430 3. Fernández-Ruiz, M. and J.M. Aguado, *Severe acute respiratory syndrome coronavirus 2 infection*
431 *in the stem cell transplant recipient - clinical spectrum and outcome.* Curr Opin Infect Dis, 2021.
432 **34**(6): p. 654-662. 10.1097/qco.0000000000000790.
- 433 4. Jefferson, T., et al., *Viral cultures, PCR Cycle threshold values and viral load estimation for*
434 *COVID-19 infectious potential assessment in transplant patients: systematic review - Protocol*
435 *Version 30 December 2021.* medRxiv, 2022: p. 2021.12.30.21268509.
436 10.1101/2021.12.30.21268509.
- 437 5. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic*
438 *reviews.* BMJ, 2021. **372**: p. n71. 10.1136/bmj.n71.
- 439 6. Aydillo, T., et al., *Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.*
440 New England Journal of Medicine, 2020. **383**(26): p. 2586-2588. 10.1056/NEJMc2031670.
- 441 7. Alshukairi, A.N., et al., *Test-based de-isolation in COVID-19 immunocompromised patients: Cycle*
442 *threshold value versus SARS-CoV-2 viral culture.* International Journal of Infectious Diseases,
443 2021. **108**: p. 112-115. 10.1016/j.ijid.2021.05.027.
- 444 8. Benotmane, I., et al., *Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients*
445 *with COVID-19.* American Journal of Transplantation, 2021. **21**(8): p. 2871-2875.
446 <https://doi.org/10.1111/ajt.16636>.
- 447 9. Tarhini, H., et al., *Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)*
448 *Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to*
449 *SARS-CoV-2 Superinfection.* The Journal of Infectious Diseases, 2021. **223**(9): p. 1522-1527.
450 10.1093/infdis/jiab075.
- 451 10. Decker, A., et al., *Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after*
452 *recent heart transplantation.* Am J Transplant, 2020. **20**(11): p. 3239-3245. 10.1111/ajt.16133.
- 453 11. Niess, H., et al., *Liver transplantation in a patient after COVID-19 - Rapid loss of antibodies and*
454 *prolonged viral RNA shedding.* Am J Transplant, 2021. **21**(4): p. 1629-1632. 10.1111/ajt.16349.
- 455 12. Weigang, S., et al., *Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19*
456 *patient: a source of immune escape variants.* medRxiv, 2021: p. 2021.04.30.21256244.
457 10.1101/2021.04.30.21256244.
- 458 13. Lang, C., et al., *Lung transplantation for COVID-19-associated acute respiratory distress*
459 *syndrome in a PCR-positive patient.* The Lancet Respiratory Medicine, 2020. **8**(10): p. 1057-1060.
460 10.1016/S2213-2600(20)30361-1.
- 461 14. Niyonkuru, M., et al., *Prolonged viral shedding of SARS-CoV-2 in two immunocompromised*
462 *patients, a case report.* BMC Infectious Diseases, 2021. **21**(1): p. 743. 10.1186/s12879-021-
463 06429-5.
- 464 15. Rajakumar, I.A.-O., et al., *Extensive environmental contamination and prolonged severe acute*
465 *respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant*
466 *recipients with clinical and virologic benefit with remdesivir.* (1559-6834 (Electronic)).

- 467 16. Jefferson, T., et al., *Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-*
468 *CoV-2) from pre and asymptomatic infected individuals. A systematic review.* Clinical
469 Microbiology and Infection, 2021. <https://doi.org/10.1016/j.cmi.2021.10.015>.
- 470 17. Jefferson, T.H., C.; Spencer, E.; Brassey, J.; Pluddeman, A.; Onakpoya, I.; Evans, D.; Conly, J. A
471 *Hierarchical Framework for Assessing Transmission Causality of Respiratory Viruses.* PrePrints,
472 2021. 10.20944/preprints202104.0633.v1.
- 473 18. Marinelli, T., et al., *Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in*
474 *Transplant Recipients.* Transplantation, 2021. **105**(10): p. 2175-2183.
475 10.1097/tp.0000000000003860.
- 476 19. Thornton, C.S., et al., *Prolonged SARS-CoV-2 infection following rituximab treatment: clinical*
477 *course and response to therapeutic interventions correlated with quantitative viral cultures and*
478 *cycle threshold values.* Antimicrob Resist Infect Control, 2022. **11**(1): p. 28. 10.1186/s13756-022-
479 01067-1.
- 480 20. van Kampen, J.J.A., et al., *Shedding of infectious virus in hospitalized patients with coronavirus*
481 *disease-2019 (COVID-19): duration and key determinants.* medRxiv, 2020: p.
482 2020.06.08.20125310. 10.1101/2020.06.08.20125310.
- 483 21. Bruce, E.A., et al., *Predicting infectivity: comparing four PCR-based assays to detect culturable*
484 *SARS-CoV-2 in clinical samples.* EMBO Mol Med, 2021: p. e15290. 10.15252/emmm.202115290.
- 485

486

487 **List of tables and figures.**

488

489 Table 1. Characteristics of transplant patients in included studies.

490

491 Table 2. Quality of included studies.

492

493 Table 3. PCR cycle counts/log copies and viral culture results of included studies.

494

495 Figure 1. PRISMA flow chart of study screening for inclusion.

496

497 Figure 2. SARs-CoV-2 culture results in transplant patients from days of symptom onset.

498

499 Figure 3. Duration of infectivity as indicated by viral culture and corresponding PCR cycle counts/log
500 copies among transplant recipients.

501

502 Figure 4. Relationship between cycle threshold and symptom onset (in days)

503

504 **List of supplementary files.**

505

506 Supplementary file. Literature search strategy.

507

508 Supplementary file. List of excluded studies, with reasons.

509

510 **Table 1.** Characteristics of transplant patients in included studies.

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Alshukairi 2021	Pt1: 34 yr F Pt2: 71 yr M Pt3: 75 yr M Pt4: 26 yr M	Pt1: cardiac, in 2014, tacrolimus, MMF, prednisolone Pt2: renal, in 2014,	Pt1: Severe pneumonia; Pt2: pneumonia	Pt1: high-flow nasal cannula Pt2: low-flow cannula

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	Pt5: 38 yr F	tacrolimus, MMF, prednisolone, DM, HTN, CAD Pt3: renal, in 2014, tacrolimus, MMF and prednisolone, HTN Pt4: renal, in 2018, tacrolimus, MMF, prednisolone, DM Pt5: renal in 2014, tacrolimus, AZA, prednisolone, APS & hypothyroidism.	Pt3: pneumonia Pt4: pneumonia Pt5: upper RTI	Pt3: low-flow cannula Pt4: oxygen not required Pt5: no cannula
Aydillo 2020	8 pts (no. of M and F and age N/A for this	Various antibiotics and immunosuppressants	Variable from mild to severe	Hydroxychloroq uine, remdesivir,

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	subset)			azythromicin, convalescent plasma
Benotmane I 2021	14 M, 2 F, median age 63.3 yrs. Pts with at least two positive for SARS-CoV-2 NP swabs (of which one collected at least 7 days after symptom onset) during the follow-up period were	16 kidney transplant recipients; median time from transplant 3.8 yrs. Antithymocyte globulin: 8/16; anti- CD25: 8/16; tacrolimus: 10/16; ciclosporin: 3/16; MMF/MPA: 14/16; mTOR inhibitors: 2/16; steroids: 10/16;	All 16 hospitalized for symptomatic COVID-19 between 4 March and 15 April 2020	lopinavir/ ritonavir: 1/16; hydroxychloroq uine: 8/16; tocilizumab: 2/16

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	eligible for inclusion	belatacept: 2/16		
Decker A 2020	62 yr M	Heart transplant Nov 2019; subsequently pneumonia and acute respiratory distress syndrome; intermittent renal replacement therapy. Cyclosporine A (target range 135 ± 30 ng/mL), mycophenolate mofetil 500 mg b.i.d., prednisone 10 mg q.d.	1 March 2020 onset of symptoms and +ve PCR; mild symptoms, no cardiorespiratory decline, several weeks +ve.	hydroxychloroquine (400mg b.i.d. + 200mg b.i.d.) from day 7 to 14

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		+ cotrimoxazole and due to cytomegalovirus high- risk constellation (D + R-), ganciclovir for 4 months post- transplantation, then valganciclovir prophylaxis.		
Lang C 2020	44 yr old F with mild untreated psoriatic arthritis and idiopathic CD4 lymphocytopen	Bilateral lung transplant day 58 after admission for Covid-19. Subsequently, standard triple	Day 0 admitted with fever, cough, +ve NP RT-PCR. Day 6 to ICU & intubation; day	Immunoglobuli ns, tocilizumab & lopinavir. Day 6 to ICU & intubation; day

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	ia	immunosuppression was initiated, including tacrolimus, mycophenolate mofetil, and steroids; also 6 additional treatment cycles of immunoabsorption and antithymocyte globulin.	13 ECMO. Day 52 preparation begun for transplant: immunoabsorption therapy; day 58 bilateral lung transplant performed. Transferred to non ICU ward day 121.	13 ECMO. Bilateral lung transplant
Niess 2020	56 yr M patient listed for liver transplantation with a Model	admission for liver transplant: 18/3/2020 positive to COVID-19 screening on		

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	For End-Stage Liver Disease Score of 19 points due to cryptogenic cirrhosis and a history of hepatitis B	25/3/2021 after 31-32 days: PCR negative + seroconversion after 36 days of symptom onset and 21 days after seronconversion: transplant; tacrolimus (to target of 4 to 7 ng/ml) + steroids		
Niyonkuru M 2021	Pt1: 66 yr M, recent liver transplant Pt2: 70 yr M,	Pt1: fatigue and tachypnea, hospital admission, tested positive for SARS-CoV- 2	Pt1 day 0 +ve test. Symptom onset day 5, diminished taste and	Pt1: In ICU, non invasive ventilation, IV dexamethason e 6 mg daily

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	previous bone marrow transplant for multiple myeloma	Pt2: pacemaker. Lenalidomide 25 mg daily. elevated CRP concentration (130 mg/L). Nocardia Farcinica was detected in blood cultures and pus from abscesses on the left leg. Trans-esophageal echocardiography showed vegetation on the pacemaker electrode.	smell; day 12 additional symptoms; day 14 hospital admission. On day 12 from symptom onset transferred to the ICU for non-invasive ventilation. Pt2 admitted on October 21 due to fever and elevated	and remdesivir: 200 mg the first day and 100 mg the following 4 days. Pt2: no COVID-19 treatment (asymptomatic)

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>CRP concentration (130 mg/L) because of systemic infection due to pacemaker contamination; periodic screening during admission; positive by week 4, always asymptomatic of COVID-19.</p>	

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Rajakumar 2021	Two cardiac transplant recipients (<3 months post-transplant): Pt1: 56 yr F; history of dilated cardiomyopathy with end-stage heart failure, type-2 diabetes mellitus, hypothyroidism, osteoporosis, and anemia.	Pt1: orthotopic heart transplant with antithymocyte globulin induction & standard triple immunosuppressive therapy & was discharged 30 days later. Pt2: orthotopic heart transplant with antithymocyte globulin induction therapy, discharged 4 weeks later.	NP swabs (& saliva & clinical & environmental samples) were collected at regular intervals beginning shortly after admission. Pt 1: 5 days post-discharge, rehospitalized following community	Pt1: after day 15, corticosteroids & antimicrobials initiated for presumptive COVID-19 pneumonitis & superimposed bacterial pneumonia; day 21 O2 requirements increased significantly. Despite

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	<p>Pt2: 33 yr F with a history of end-stage heart failure 2ndary to congenital heart disease, liver cirrhosis & kidney disease.</p>	<p>Pt1 and Pt2: prednisone, tacrolimus, and mycophenolate mofetil, and standard prophylactic medications</p>	<p>exposure to COVID-19. Nasal stiffness & discharge, sneezing, fatigue & cough developed on admission day 4; NP swab +ve for SARS-CoV- 2. All symptoms except fatigue resolved by day 12.</p>	<p>discontinuation of MMF & reduction of tacrolimus, cultivable viral loads increased in the NP & saliva; chest radiograph & clinical condition deteriorated; mechanical ventilation considered. 10- day course of</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>Dyspnea, cough & hypoxia then developed on day 15; chest radiograph revealed new bibasilar interstitial infiltrates. Discharged day 44.</p> <p>Pt2: tested +ve for SARS-CoV-2 shortly after discharge,</p>	<p>remdesivir initiated day 27. Clinical condition & chest radiograph improved; O2 discontinued day 32; discharged day 44.</p> <p>Pt2: intubation. MMF dose was reduced; dexamethason e &</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>readmitted 1 week later with progressive dyspnea & hypoxemia requiring intubation.</p> <p>Significant viable virus burdens were noted in the NP swab (& saliva, & a used face cloth) 16 days after</p>	<p>antimicrobials initiated. MMF was subsequently held & later restarted when an echocardiogram demonstrated a reduction in left ventricular systolic function, suggesting acute graft rejection.</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			initial SARS-CoV-2 positivity. 5-day course remdesivir initiated followed by clinical recovery & discharge 7 days later.	Pt1: 10-day course of remdesivir from day 27 to day 37 from hospital admission; improvement and subsequent discharge on day 44 Pt2: 5-day course remdesivir,

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
				improvement and discharge 7 days later
Tarhini 2021	71yr European M	Cardiac transplant, also diabetes mellitus & chronic kidney disease; prednisone, mycophenolic acid, belatacept	15 April 2020 hospitalized for asthenia, dry cough, myalgia, and low-grade fever for 1 week. No dyspnea or O2 need. +ve on admission and day 14 with <10% Covid-19	At readmission, treated in ICU for cardiac decompensatio n due to underlying respiratory infection. [Unclear what happened after this; last test day 121 & culture +ve at

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>involvement on CT scan. Discharged day 39 after clinical improvement, despite persistent +ve PCR at day 32 (21 Ct). 23 June readmitted with dry cough, dyspnea, and O2 requirement.</p>	<p>day 103, negative serology throughout]</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Weigang 2021	58 yr M	kidney transplant, also CHD, arterial hypertension, hyperlipidemia, obesity; basiliximab (20mg, day 0 and day 4 post-transplantation) and prednisone (250mg at day 0, 125 mg day 1, 50mg day 2 to 5, 20mg day 6 to 10, then 15 mg/day). Additionally tacrolimus (10mg day 0, 8mg day 1,	March 2020, mild respiratory symptoms & tested positive for SARS-CoV-2 for over 145 days; discharged on day 72 for home quarantine; re-hospitalized at day 106 to 126 due to another kidney transplant	Ivermectin 4 day course (33mg/day, day 56 to 60); 10 day course remdesivir (200 mg on day 140, then 100 mg/daily, day 141 to 149)

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		5.5mg day 2, 5mg day 3 and 4, then 4mg/day) and Mycophenolate mofetil (2000mg/day). Maintenance immunosuppression consisted of tacrolimus (4 to 6mg/day), mycophenolate mofetil (2,000mg/day), and prednisone (10 to 20mg/day)	failure. Days 140 to 149 treated with remdesivir; subsequent PCR tests negative & virus isolation negative.	

511 Abbreviations:

512 APS = anti-phospholipid syndrome

- 513 AZA = azathioprine
- 514 CAD = coronary artery disease
- 515 DM = diabetes mellitus
- 516 HTN = hypertension
- 517 MMF = mycophenolate mofetil
- 518 NP = nasopharyngeal
- 519 Pt = patient
- 520 RTI = respiratory tract infection
- 521 RT-PCR = reverse transcriptase polymerase chain reaction
- 522

523 **Table 2.** Quality of included studies.

Study ID	Were the criteria for diagnosing a case clearly reported and appropriate ?	Was the reporting of patient/ population characteristic s adequate?	Was the study period, including follow-up, sufficient?	Were the methods used to obtain RT-PCR results replicable and appropriate?	Were the methods used to obtain viral culture results replicable and appropriate?
Alshukairi 2021	Unclear*	No**	Yes	Yes	Unclear
Aydillo 2020	Unclear	Yes	Yes	Unclear	Yes
Benotmane I 2021	Yes	Yes	Yes	Yes	No***
Decker A 2020	No	Yes	Yes	Unclear	Unclear
Lang C 2020	Yes	Yes	Yes	Unclear	Unclear
Niess 2020	Yes	Yes	Yes	Yes	Unclear
Niyonkuru M 2021	No*	Yes	Yes	Yes	Yes
Rajakumar 2021	Yes	Yes	Yes	Yes	Yes

Tarhini 2021	Yes	Yes	Yes	Yes	Yes
Weigang 2021	Yes	Yes	Yes	Yes	Yes

524

525 *case definition unclear, article reports positive RT-PCR, but Ct cut-off not reported.

526 ** data on clinical symptoms lacking

527 ***The cell line used was not one that is demonstrated to support SARS-CoV-2 growth.

528 Therefore the cell culture results are not reliable.

529

530 **Table 3.** PCR cycle counts/log copies and viral culture results of included studies.

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
Alshukairi 2021	NR no viral culture at admission/ons et of symptoms	Pt1: D3: positive, Ct NA, D26: positive, 22.87 Pt2: D3: positive, 11.58; D17: positive, 23.12 Pt3: D6: positive, 8.82, D19: positive, 13.88 Pt4: D4: positive, 10.38; D12: positive, 27.57 Pt5: D1: positive, 2.8, D9: positive, 14.84	Pt1: D26: negative Pt2: D17: negative Pt3: D19: negative Pt4: D12: negative Pt5: D9: negative
Aydillo 2020 *	All symptomatic; variable severity	Pt1: D3: 22.5, D27: 34 Pt2: D2: 18, D27: 32 Pt4: D5: 19, D28: 18.5, D50: 27.5 Pt6: D18: 21, D27: 21.5, D33: 30.5, D38: 20, D45: 19.5, D52:	Pt1 D3: positive, D27: negative Pt2: D2: positive, D27, negative Pt4: D5: positive, D28: positive, D50: negative Pt6: D18: negative, D27: negative, D33: negative, D38:

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		<p>20, D62: 18.5</p> <p>Pt8: D1: 22, D17: 21, D22: 22, D37: 35</p> <p>Pt9: D4: 13, D8: 22, D46: 33.5, D56: 27, D82: 38</p> <p>Pt13: D2: 21.5, D50: 31.5</p> <p>Pt14: D8: 17.5</p>	<p>negative, D45: positive, D52: positive, D62: positive</p> <p>Pt8: D1: positive, D17: positive, D22: negative, D37: negative</p> <p>Pt9: D4: positive, D8: positive, D46: negative, D56: negative, D82: negative</p> <p>Pt13: D2: positive, D50: negative</p> <p>Pt14: D8: positive</p>
Benotmane 2021		<p>Patient 6: D23: Ct > 30; D29: Ct > 35</p>	<p>Pt1: D5, D14: negative;</p> <p>Pt2: D21, D29: negative;</p> <p>Pt3: D25, D39: negative</p> <p>Pt4: D2: positive, D9, D16, D35: negative</p> <p>Pt5: D1, D8: positive; D23, D30: negative</p>

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		Patient 7: D38: Ct > 35 Patient 8: D28: Ct > 30 Patient 11: D27: Ct > 30	Pt6: D6, D9, D23, D29: positive Pt7: D7, D38: positive Pt8: D1: negative, D8, D28: positive Pt9: D11: negative, D30: negative Pt10: D2, D8: negative Pt11: D11, D27: positive Pt12: D17, D27: negative Pt13: D2, D9: positive; D31: negative Pt14: D3, D19: negative Pt15: D4, D17: negative Pt16: D20: positive, D30: negative.
Decker 2020	Mild symptoms. Day 0: transient	PCR +ve on days 1, 5, 7, 11, 18, 21, 25, 28, 33, and still on day 35 PCR remained positive on day 35	Viral culture +ve at day 18 and day 21 post-onset of symptoms.

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
	<p>episode of fever & sore throat ; day 7 temperature increase; no clinical symptoms after day 20.</p>	<p>with copy numbers similar to the onset of infection. Concurrent with the second onset of fever there was an increased viral load after day 7 that slowly returned to the level of infection onset.</p>	
Lang 2020	<p>Admitted with fever & cough becoming severe and life threatening leading to bilateral lung transplant.</p>	<p>Day 0, Ct 27; Day 17, Ct 21; Day 23, Ct 23; Day 19, Ct 32; Day 31, Ct 32; Day 36, Ct 29; Day 48, Ct 39; Day 53, Ct 34; Day 59, Ct 33; Day 61, PCR negative; Day 62, Ct 36; Day 62, PCR negative; Day 64, PCR negative; Day 65, Ct 36; Day 66, Ct 39; Day 69, Ct 39; Day 70, PCR negative; Day 72, PCR negative; Day 74, PCR negative;</p>	<p>Samples cultured from day 48 and day 65; both negative by cell culture.</p>

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		Day 76, PCR negative; Day 95, PCR negative;	
Niess 2020	Mild symptoms of malaise and a dry cough	day 0: positive but asymptomatic day 8, 12, 19, 22 - positive PCR day 31, 32 - negative PCR day 49, 55, 60 - positive PCR day 58, 63, 64 - negative PCR results	Positive pre-transplant PCRs were not confirmed by cell cultures 4 negative viral cell culture results from samples taken on days 49, 54, 60 and 69 (*)
Niyonkuru 2021	Pt1: fatigue and tachypnea, then ventilation required. Pt2:	Pt1: day 15 from 1st positive PCR/day 3 from symptoms onset: Cq 21.7; day 21 from 1st positive PCR/day 9 from symptoms onset: Cq 19.21; day 43 from 1st positive PCR/day 13 from symptoms onset Cq 35.45	Pt1: day 15 from 1st positive PCR/day 3 from symptoms onset viral culture at 61,277 PFU/swab; day 21 from 1st positive PCR/day 9 from symptoms onset viral culture at 256,410 PFU/swab;

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
	asymptomatic for COVID-19.	Pt2: day 9 from 1st positive PCR: Cq: 22.33; day 12 from 1st positive PCR Cq 22.57; day 14 from 1st positive PCR: Ct approx 33.5; day 18 from 1st positive PCR: PCR negative.	day 22 from 1st positive PCR/day 13 from symptoms onset viral culture negative. Pt2: day 9 from 1st positive PCR: culture positive with 11082 PFU/swab; day 12 from 1st positive PCR: culture positive with PFU 55944/swab; day 14 from 1st positive PCR: culture negative.
Rajakumar 2021		Pt 1: hospital admission, positive PCR day 4 post-symptom onset Day 4: N gene Ct 16, E gene Ct 19 Day 12: N gene Ct 13, E gene Ct 20	Pt1 Viral culture Day 4: positive Day 12: positive Day 20: positive Day 27: positive

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		Day 20: N gene Ct 14, E gene Ct 19 Day 27: N gene Ct 15, E gene Ct 21 Day 32: N gene Ct 32, E gene Ct 28 Day 60: N gene Ct 30, E gene Ct 35 Pt 2: Day 16: N gene Ct 14, E gene Ct 20 Day 22: N gene Ct 25, E gene Ct 33 Day 25: N gene Ct 25, E gene 29 Day 42: N gene Ct 29, E gene Ct 37 Day 51: N gene Ct 37, E gene Ct 39	Day 32: negative Day 60: negative Pt 2: Viral culture Day 16: positive Day 22: negative Day 25: negative Day 42: negative Day 51: negative

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
Tarhini 2021	Severe infection requiring intensive care	Day 6: Ct=25, Day 16: Ct=24 Day 32: Ct=20 Day 78: Ct=34 Day 80: Ct=24 Day 91: Ct=28 Day 103: Ct=23 Day 109: Ct=18 Day 120: Ct=26 Day 132: Ct=40+ (negative) Day 136: Ct=40+ (negative) (*)	Day 6: culture negative Day 16: culture negative Day 80: culture negative Day 91: culture negative Day 103: culture positive Day 111: culture negative Day 120: culture negative (*)
Weigang 2021	Mild respiratory symptoms for over 145 days	38 PCR tests: days 0, 6, 10, 14, 16, 21, 24, 27, 31, 34, 38, 42, 45, 46, 49, 52, 56, 58, 63, 65, 71, 105, 113, 115, 119, 122, 126, 140, 143, 145, 146, 149, 150,	27 cell culture tests, days: 0, 6, 10, 14, 16, 21, 24, 27, 31, 34, 38, 42, 45, 49, 52, 56, 58, 63, 65, 71, 105, 106, 113, 115, 119, 140, 154; 27 results: -, +, +, +, -,

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
		154, 161, 167, 174, 189. 38 Ct values: 25, 16, 19, 19, 25, 23, 18, 26, 20, 17, 31, 27, 27, 50, 27, 28, 25, 28, 27, 29, 30, 23, 34, 29, 31, 31, 36, 26, 29, 34, 39, 45, 45, 34, 45, 45, 45, 45.	+, +, ++, +, -, -, -, -, -, -, -, -, +, -, -, -, -, -, (i.e. positive on days 6, 10, 14, 21, 24, 27, 31, 34, 105)

531

532

533 (*) Numbers have been read from a figure in the published article and may not be an accurate
 534 estimate.

535

536 Ct = cycle threshold

537 D = day

538 NR = not reported

539 NA = not available

540 Pt = patient

541 RT-PCR = reverse transcriptase polymerase chain reaction

Figure 1. PRISMA flow chart of study screening for inclusion.





Figure 2. SARS-CoV-2 culture results in transplant patients from days of symptom onset.



Culture positive (n=59 samples): median 16 (IQR 8-27, Range 1-105 days, mean 19.7 days
Culture negative (n=107 samples): median 40 (IQR 22-60), Range 1-119 days, mean 43.2 days

Figure 3a. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results
 Alshukairi [7], Benotmane [8], Rajakumar [15] & Niyonkuru [14] (days 1- 42)







Figure 3b. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results
 Aydillo [6] (day 1-90), Tarhini [9] & Weigang [12] (day 1-120)



■ Negative Culture
■ Positive Culture
 Number equals RT-PCR Cycle Threshold

Figure 3c. Timings of positive culture results in Transplant Patients by duration of symptoms and log10 copies/ml results
 Decker ^[10] (days 1-36)

	patient	D0	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	D12	D13	D14	D15	D16	D17	D18	D19	D20	D21	D22	D23	D24	D25	D26	D27	D28	D29	D30	D31	D32	D33	D34	D35	D36
Decker 2020 log10 copies/ml, > 4 log10 deemed +ve	1		4.5				4		6				6.2							6.2			6.5				5		4.5						4		4	

- Negative Culture
- Positive Culture
- Number equals log copies/ml

Figure 4. Relationship between cycle threshold, symptom onset (in days) and likelihood of shedding replication competent virus

